IRBESARTAN tablet

Land: USA

Språk: engelska

Källa: NLM (National Library of Medicine)

Aktiva substanser:

IRBESARTAN (UNII: J0E2756Z7N) (IRBESARTAN - UNII:J0E2756Z7N)

Tillgänglig från:

Solco Healthcare U.S., LLC

INN (International namn):

IRBESARTAN

Sammansättning:

IRBESARTAN 75 mg

Administreringssätt:

ORAL

Receptbelagda typ:

PRESCRIPTION DRUG

Terapeutiska indikationer:

Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with differe

Produktsammanfattning:

Irbesartan tablets are available as white to off-white biconvex oval tablets, debossed with “HH” on one side and a code on the other (see Table below). Unit-of-use bottles contain 30, 90 or 500 tablets as follows: 75 mg 150 mg 300 mg Debossing 329 330 331 Bottle of 30 43547-374-03 43547-375-03 43547-376-03 Bottle of 90 43547-374-09 43547-375-09 43547-376-09 Bottle of 500 43547-374-50 43547-375-50 43547-376-50

Bemyndigande status:

Abbreviated New Drug Application

Produktens egenskaper

IRBESARTAN- IRBESARTAN TABLET
SOLCO HEALTHCARE U.S., LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
IRBESARTAN TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
IRBESARTAN TABLETS.
IRBESARTAN TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1997
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•
•
INDICATIONS AND USAGE
Irbesartan tablets are an angiotensin II receptor blocker (ARB)
indicated for:
•
•
DOSAGE AND ADMINISTRATION
INDICATION DOSE
Hypertension (2.2)
150 to 300 mg once daily
Diabetic Nephropathy (2.3)
300 mg once daily
DOSAGE FORMS AND STRENGTHS
•
CONTRAINDICATIONS
•
•
WARNINGS AND PRECAUTIONS
•
•
ADVERSE REACTIONS
•
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT SOLCO HEALTHECARE US
LLC. AT 1-866-
257-2597 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
•
•
WHEN PREGNANCY IS DETECTED, DISCONTINUE IRBESARTAN TABLETS AS SOON AS
POSSIBLE.
(5.1, 8.1)
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH
TO THE DEVELOPING FETUS. (5.1, 8.1)
Treatment of hypertension, to lower blood pressure. Lowering blood
pressure reduces the risk of fatal
and nonfatal cardiovascular events, primarily strokes and myocardial
infarctions. (1.1)
Treatment of diabetic nephropathy in hypertensive patients with type 2
diabetes, an elevated serum
creatinine, and proteinuria. (1.2)
Tablets: 75 mg, 150 mg, 300 mg (3)
Hypersensitivity to any component of this product. (4)
Coadministration with aliskiren in patients with diabetes. (4)
Hypotension: Correct volume or salt depletion prior to administration.
(5.2)
Monitor renal function and serum potassium. (5.3)
NEPHROPATHY IN TYPE 2 DIABETIC PATIENTS: THE MOST COMMON ADVERSE
REACTIONS WHICH
WERE MORE FREQUENT THAN PLACEBO WERE HYPERKALEMIA DIZZINESS,
ORTHOSTATIC DIZZINESS,
AND ORTHOSTATIC HYPOTENSION. (6.1)
Lithium: Risk of lithium toxicity. (7)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) a